Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with 67Cu

Radionuclide therapy targeting prostate-specific membrane antigen (PSMA) is promising for prostate cancer. We previously reported a ligand, 64Cu-CuSarbisPSMA, featuring 2 lysine-ureido-glutamate groups. Here, we report the therapeutic potential of 67Cu-CuSarbisPSMA. Methods: Growth of PSMA-positive xenografts was evaluated after treatment with 67Cu-CuSarbisPSMA or 177Lu-LuPSMA imaging and therapy (I&T). Results: At 13 d after injection, tumor growth was similarly inhibited by the 2 tracers in a dose-dependent manner. Survival was comparable after single (30 MBq) or fractionated (2 center dot 15 MBq, 2 wk apart) administrations. Conclusion: 67Cu-CuSarbisPSMA is efficacious in a PSMA-expressing model of prostate cancer.

Automated summary

67Cu-CuSarbisPSMA demonstrates therapeutic potential in a PSMA-expressing model of prostate cancer, with the ability to inhibit tumor growth and improve survival rates.